
HRMY Stock Forecast & Price Target
HRMY Analyst Ratings
Bulls say
Harmony Biosciences Hldgs is well-positioned for long-term success due to their central nervous system pipeline and WAKIX's potential as a blockbuster drug with expected sales of over $700 million in 2024. The company's therapeutic focus on rare neurological disorders offers significant growth potential, and their strong financials and emphasis on research and development make them an attractive investment opportunity.
Bears say
Harmony Biosciences Hldgs is facing potential challenges in differentiating its product WAKIX in the hypersomnolence market and expanding its indications, with competition from other once-daily neuropsychiatric drugs and potential sales plateau before loss-of-exclusivity. Additionally, its IP legal barriers may not be strong enough to protect against potential generic competition, and future growth may depend on in-licensing new pipeline assets. With limited cash reserves, Harmony Biosciences Hldgs may struggle to sustain profitability and may face risks in demonstrating sufficient safety and efficacy for its current pipeline assets.
This aggregate rating is based on analysts' research of Harmony Biosciences Holdings and is not a guaranteed prediction by Public.com or investment advice.
HRMY Analyst Forecast & Price Prediction
Start investing in HRMY
Order type
Buy in
Order amount
Est. shares
0 shares